Stock Events

Nanomix 

$0
5
+$0+0% Friday 18:25

Statistics

Day High
0
Day Low
0
52W High
0.95
52W Low
0
Volume
174
Avg. Volume
62
Mkt Cap
4,900
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

14NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-3.52
-2.35
-1.17
-0
Expected EPS
N/A
Actual EPS
-0.08

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NNMX. It's not an investment recommendation.

About

Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.
Show more...
CEO
Employees
30
Country
US
ISIN
US63008H2013

Listings